Pharmaceutical composition for treatment of dementia and cerebrovascular disorders
The disclosures as described herein a pharmaceutical composition for preventing or treating a cerebrovascular disorder or a vascular dementia, or suppressing a progression of the diseases in a subject in need of the treatment and so on, the composition comprising one or more compounds selected from the following group, and a pharmaceutically acceptable carrier; and a method using the same. A group consisting of apomorphine, eseroline, ethoxyquin, methyldopa, olanzapine, indapamide, and the others.
1 . A method for suppressing a progression of vascular dementia, comprising administering a therapeutically effective amount of one or more compounds selected from the group consisting of ethoxyquin and methyldopa to a subject in need thereof,
wherein a dosage of methyldopa and ethoxyquin are each in a range from 0.001 to 50 mg/kg weight per day.
2 . The method for suppressing the progression of the vascular dementia according to claim 1 , wherein the subject is a mammal.
3 . The method for suppressing the progression of the vascular dementia according to claim 1 , wherein the subject is a human.
4 . The method for suppressing the progression of the vascular dementia according to claim 1 , wherein the subject suffers from early-onset dementia.
5 . The method for suppressing the progression of vascular dementia according to claim 1 , comprising administering to a subject in need thereof a food or beverage containing a therapeutically effective amount of one or more compounds selected from the group consisting of ethoxyquin and methyldopa.
6 . The method of claim 5 , wherein the dosage of methyldopa and ethoxyquin are each in a range from 0.1 to 50 mg/kg weight per day.
7 . The method of claim 5 , wherein the ethoxyquin or the methyldopa is administered once per day, or a plural times per day, or is administered once or a plural times within several days or several weeks.
8 . The method of claim 1 , wherein the dosage of methyldopa and ethoxyquin are each in a range from 0.1 to 50 mg/kg weight per day when administered orally or intraperitoneally.
9 . The method of claim 8 , wherein the dosage of methyldopa and ethoxyquin are each in a range from 0.2 to about 10 mg/kg weight per day.
10 . The method of claim 9 , wherein the dosage of methyldopa and ethoxyquin are each in a range from 0.3 to about 2 mg/kg weight per day.
11 . The method of claim 10 , wherein the dosage of methyldopa and ethoxyquin are each in a range from 0.4 to about 1 mg/kg weight per day.
12 . The method of claim 1 , wherein the ethoxyquin or the methyldopa is administered once per day, or a plural times per day, or is administered once or a plural times within several days or several weeks.